Related Experiment Videos
Clinicopathologic features and long-term outcomes of NUT midline carcinoma
Daniel E Bauer1, Chelsey M Mitchell, Kelly M Strait
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.
Purpose:
NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer characterized by rearrangement of the NUT gene. Research advances have provided opportunities for targeted therapy in NMC, yet the clinical features of this rare disease have not been systematically characterized. We report on a large population of such patients to identify the disease characteristics and treatments, correlate them with outcome, and to consider clinical recommendations.
Experimental Design:
A clinical database was established using retrospective demographic and outcomes data available on all known cases of NMC. Questionnaires were completed by treating physicians. Pathologic, demographic, and clinical variables were assessed for 63 patients, the largest cohort of patients with NMC studied to date. Outcome data from 54 patients were available for survival analyses.
Results:
The diagnosis of NMC has increased annually since 2007. Since 2009, there has been an observed increase in the age at diagnosis (P < 0.05). Geographic distribution of patients with NMC has been concentrated in the United States (n = 41, 65%). The median overall survival for patients with NMC was 6.7 months. The 2-year progression-free survival (PFS) was 9% with a 95% confidence interval (CI) of 1% to 17% [1-year PFS 15% (5-24%) and 2-year overall survival (OS) was 19% with a 95% CI of 7%-31% (1-year OS: 30% (27-34%)]. Multivariate analysis suggested that extent of surgical resection and initial radiotherapy were independent predictors of PFS and OS. Notably, no chemotherapeutic regimen was associated with improved outcome.
Conclusions:
NMC portends a poor prognosis among all squamous cell neoplasms and seems to be frequently unrecognized. The finding that conventional chemotherapy has been inadequate indicates a pressing need for the development of targeted therapeutics. Intensive local therapies such as gross total resection and radiotherapy might be associated with enhanced survival.
Insights
NUT midline carcinoma (NMC) is a rare, aggressive squamous cancer. Intensive local therapies like surgery and radiotherapy may improve survival, as conventional chemotherapy is ineffective for this disease.
Area of Science:
- Oncology
- Cancer Research
- Genetics
Background:
- NUT midline carcinoma (NMC) is a rare, poorly differentiated squamous cell neoplasm defined by NUT gene rearrangements.
- Despite advances, the clinical characteristics and treatment outcomes for NMC remain poorly understood.
- This study aims to systematically characterize NMC to inform clinical recommendations.
Purpose of the Study:
- To identify disease characteristics and treatments for NUT midline carcinoma.
- To correlate clinical features with patient outcomes.
- To provide clinical recommendations for managing NMC.
Main Methods:
- Retrospective analysis of a clinical database of all known NMC cases.
- Data collection via questionnaires completed by treating physicians.
- Assessment of pathologic, demographic, and clinical variables in 63 patients; survival analyses performed on 54 patients.
Main Results:
- The diagnosis of NMC has increased annually since 2007, with a trend toward older age at diagnosis since 2009.
- The majority of identified cases (65%) were concentrated in the United States.
- Median overall survival was 6.7 months; 2-year progression-free survival was 9%. Surgical resection extent and initial radiotherapy were independent predictors of survival, while chemotherapy showed no benefit.
Conclusions:
- NUT midline carcinoma has a poor prognosis and is often underrecognized.
- Conventional chemotherapy is inadequate for NMC, highlighting the need for targeted therapies.
- Aggressive local treatments, including complete surgical resection and radiotherapy, may improve survival outcomes.